Equities research analysts predict that Insys Therapeutics Inc (NASDAQ:INSY) will report earnings of ($0.11) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Insys Therapeutics’ earnings, with estimates ranging from ($0.13) to ($0.10). Insys Therapeutics reported earnings of $0.03 per share during the same quarter last year, which would indicate a negative year over year growth rate of 466.7%. The firm is scheduled to issue its next quarterly earnings results on Monday, April 2nd.
According to Zacks, analysts expect that Insys Therapeutics will report full year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.41) to ($0.32). For the next financial year, analysts forecast that the company will report earnings of ($0.48) per share, with EPS estimates ranging from ($0.88) to ($0.27). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Insys Therapeutics.
Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.02). Insys Therapeutics had a negative return on equity of 11.76% and a negative net margin of 112.56%.
Several hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its stake in shares of Insys Therapeutics by 0.5% in the second quarter. Wells Fargo & Company MN now owns 27,667 shares of the specialty pharmaceutical company’s stock valued at $350,000 after acquiring an additional 126 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Insys Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 79,943 shares of the specialty pharmaceutical company’s stock valued at $1,012,000 after acquiring an additional 475 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Insys Therapeutics by 4.5% in the second quarter. The Manufacturers Life Insurance Company now owns 21,576 shares of the specialty pharmaceutical company’s stock valued at $274,000 after acquiring an additional 938 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Insys Therapeutics by 3.7% in the second quarter. Teachers Advisors LLC now owns 45,016 shares of the specialty pharmaceutical company’s stock valued at $569,000 after acquiring an additional 1,604 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Insys Therapeutics by 6.1% in the second quarter. Rhumbline Advisers now owns 30,970 shares of the specialty pharmaceutical company’s stock valued at $392,000 after acquiring an additional 1,793 shares in the last quarter. Institutional investors and hedge funds own 25.33% of the company’s stock.
Shares of Insys Therapeutics (NASDAQ INSY) opened at $8.80 on Monday. The company has a market cap of $645.19, a price-to-earnings ratio of -3.45 and a beta of 0.78. Insys Therapeutics has a 1 year low of $4.10 and a 1 year high of $15.02.
TRADEMARK VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/05/analysts-anticipate-insys-therapeutics-inc-insy-to-post-0-11-earnings-per-share.html.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.